K

KeyMed Biosciences Inc
HKEX:2162

Watchlist Manager
KeyMed Biosciences Inc
HKEX:2162
Watchlist
Price: 38.2 HKD -3.29% Market Closed
Market Cap: 10.5B HKD
Have any thoughts about
KeyMed Biosciences Inc?
Write Note

KeyMed Biosciences Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

KeyMed Biosciences Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
K
KeyMed Biosciences Inc
HKEX:2162
Revenue
ÂĄ354.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Revenue
ÂĄ17.4B
CAGR 3-Years
102%
CAGR 5-Years
68%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Revenue
ÂĄ5.5B
CAGR 3-Years
33%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Revenue
ÂĄ8.3B
CAGR 3-Years
37%
CAGR 5-Years
31%
CAGR 10-Years
27%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Revenue
ÂĄ46.7B
CAGR 3-Years
30%
CAGR 5-Years
42%
CAGR 10-Years
51%
Imeik Technology Development Co Ltd
SZSE:300896
Revenue
ÂĄ2.9B
CAGR 3-Years
59%
CAGR 5-Years
55%
CAGR 10-Years
N/A
No Stocks Found

KeyMed Biosciences Inc
Glance View

Market Cap
10.7B HKD
Industry
Biotechnology

Keymed Biosciences, Inc. is an investment holding company. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2021-07-08. The firm focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The firm has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The firm has also established a fully integrated platform covering the key functions of biopharmaceutical development. The firm's main products include CM310, CM326 and CMG901.

Intrinsic Value
37.36 HKD
Overvaluation 2%
Intrinsic Value
Price
K

See Also

What is KeyMed Biosciences Inc's Revenue?
Revenue
354.1m CNY

Based on the financial report for Dec 31, 2023, KeyMed Biosciences Inc's Revenue amounts to 354.1m CNY.

What is KeyMed Biosciences Inc's Revenue growth rate?
Revenue CAGR 1Y
254%

Over the last year, the Revenue growth was 254%.

Back to Top